Connect Biopharma Holdings Limited
CNTBDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
CNTB Earnings Report
EPS Est: $-0.32 | FQ end 2026-06
CBP-201
Moderate to Severe Persistent Asthma
Double-Blind 0.2mg CBP-307
Moderate to Severe Ulcerative Colitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CBP-201 | Phase 2 | Moderate to Severe Persistent Asthma | - | - |
Double-Blind 0.2mg CBP-307 | Phase 2 | Moderate to Severe Ulcerative Colitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Connect Biopharma Holdings Limited's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Connect Biopharma Holdings Limited's (CNTB) pipeline across Phase 2. Its lead program is CBP-201 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Connect Biopharma Holdings Limited's next FDA catalyst?→
Connect Biopharma Holdings Limited's (CNTB) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CNTB biotech catalysts?→
Add CNTB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Connect Biopharma Holdings Limited's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.